Genomic Testing and Biomarker-Driven Treatment Selection in Advanced Prostate Cancer

Key Takeaways:

• Molecular biomarkers now shape advanced prostate cancer decisions – and not all point toward targeted therapy. Some markers indicate chemotherapy responsiveness instead.
• Current guidance recommends both germline and somatic biomarker testing in metastatic prostate cancer. Liquid-biopsy testing is an increasingly viable alternative when tumor tissue is limited.
• Test at metastatic diagnosis, not at the decision point – sequencing can take weeks. Integrate results by recognizing whether findings point toward targeted therapy, chemotherapy, or another treatment option.

Genomic and biomarker testing in advanced prostate cancer has shifted from a niche subspecialty consideration to a foundational element of decision-making. Metastatic disease often carries identifiable molecular subsets that influence treatment selection at every line. And current National Comprehensive Cancer Network (NCCN) guidance reflects a testing landscape where both germline and somatic information shape the available options.¹

The clinical implications are not uniform – some biomarker findings point toward targeted therapy; others may point toward different options, such as chemotherapy. Both directions belong in the modern advanced prostate cancer (PC) genomic landscape.

Targeted-therapy biomarkers

Up to approximately 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor alterations in genes involved in DNA damage repair. In the PROfound trial, olaparib improved imaging-based progression-free survival (iPFS) versus enzalutamide or abiraterone therapy in patients with homologous recombination repair (HRR)-altered mCRPC who had progressed on prior new hormonal therapy – median iPFS 7.4 vs 3.6 months in the BRCA1/BRCA2/ATM cohort, hazard ratio (HR) 0.34.²

TRITON3 showed similar benefit for rucaparib (versus physician choice of second-generation androgen-receptor pathway inhibitor or docetaxel) in BRCA-altered mCRPC (median iPFS 11.2 vs 6.4 months; HR 0.50), with no clear benefit in the ATM subgroup.³

In TALAPRO-2, talazoparib + enzalutamide improved radiographic progression-free survival (rPFS) over enzalutamide alone in HRR-mutated first-line mCRPC (median not reached vs 13.8 months; HR 0.45).⁴

Microsatellite instability-high (MSI-H), tumor mutational burden-high (TMB-H), or mismatch repair-deficient (dMMR) status carries a tumor-agnostic immune checkpoint inhibitor (ICI) indication. Across an unselected mCRPC population, single-agent pembrolizumab shows modest activity (objective response rate approximately 3 to 5% in KEYNOTE-199), reinforcing that biomarker-selected MSI-H/TMB-H/dMMR candidacy is the indication path where checkpoint inhibition is most clearly considered.^1,5

Androgen-receptor splice variant 7 (AR-V7) mRNA detection in circulating tumor cells has been associated with markedly reduced prostate-specific antigen (PSA) response and shorter PSA progression-free survival on enzalutamide and abiraterone in early prospective work. Where assessed, AR-V7 status helps inform whether the next line should remain AR-targeted or shift mechanism.⁶

Biomarkers pointing toward chemotherapy

A defined molecular subset within mCRPC carries combined alterations in tumor suppressor genes – at least 2 of RB1, TP53, and/or PTEN – and this signature characterizes aggressive variant prostate cancer (AVPC).⁷

Clinically, AVPC is recognized by visceral metastases, low PSA relative to disease burden, bulky tumors, elevated lactate dehydrogenase (LDH), elevated carcinoembryonic antigen (CEA), lytic bone metastases, or neuroendocrine differentiation; the entity is associated with a chemotherapy-responsive biology distinct from typical adenocarcinoma.^1,7

In a 120-patient phase 2 trial, first-line carboplatin-docetaxel yielded a 65% progression-free rate after four cycles in patients meeting prospectively defined clinical criteria for the aggressive variant phenotype; responses were frequent but of short duration. Current NCCN guidance lists cabazitaxel-carboplatin or docetaxel-carboplatin among the molecular-biomarker-directed options for AVPC mCRPC. When the molecular profile points to AVPC features, the higher-yield class consideration is taxane chemotherapy – alone or in platinum-taxane combinations – rather than continued targeted therapy.^1,8

Testing modalities and timing

Germline testing identifies inherited variants relevant to family risk and treatment; somatic profiling identifies tumor-specific alterations relevant to next-line selection. NCCN recommends both germline HRR testing and somatic profiling for HRR, MSI/dMMR, and tumor mutational burden (TMB) in metastatic prostate cancer.¹

Tissue-based next-generation sequencing (NGS) remains standard, but matched comparisons of plasma circulating tumor DNA (ctDNA) and metastatic tissue biopsy demonstrated 89% concordance in clinically actionable copy-number calls, supporting ctDNA as a viable alternative when archival tissue is limited. NGS turnaround typically runs over days to weeks – a reason to test at metastatic diagnosis rather than at the decision point.⁹

Insurance coverage for somatic and germline testing varies by setting and payer. Germline-positive findings require genetic-counseling integration. Each class – PARP, ICI, AR-targeted, and taxane chemotherapy – carries distinct adverse-event profiles and contraindication considerations; class-level safety should be reviewed in current prescribing information at the time of decision.

The framework is straightforward: what is the molecular profile, what direction does it point (targeted vs cytotoxic (or other)), and how does that integrate with the patient's prior treatment, performance status, and goals? In the Prostate Cancer In America 2025 survey, 41% of mCRPC respondents identified clinical trials as a top content interest – an indicator that this patient population is broadly receptive to biomarker-informed trial discussions.¹⁰